Robust prostate-specific expression for the targeted gene therapy based on the human kallikrein 2 promoter.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Urology

• Publication date

  2002-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0022-5347(05)64813-6PMID 12136877
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Targeting strategies of adenovirus-mediated gene therapy and virotherapy for prostate cancer

  2017cites this paper
• Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells

  2014cites this paper
• Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy

  2011cites this paper
• Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter

  2009cites this paper
• A novel hTERT promoter–driven E1A therapeutic for ovarian cancer

  2009cites this paper
• Enhancement of gene transactivation activity of androgen receptor by hepatitis B virus X protein.

  2007cites this paper
• Advances in preclinical investigation of prostate cancer gene therapy.

  2007cites this paper
• Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system.

  2006cites this paper
• The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells.

  2005cites this paper
• Gene therapy and immunotherapy of prostate cancer: Adenoviral-based strategies

  2005cites this paper
• Promoters and control elements: designing expression cassettes for gene therapy.

  2004cites this paper
• Endocrine aspects of cancer gene therapy.

  2004cites this paper
• Integrated, molecular engineering approaches to develop prostate cancer gene therapy.

  2003cites this paper
• Baculoviruses as Vectors for Gene Therapy against Human Prostate Cancer

  2003cites this paper
• Transcriptional Targeting in Cancer Gene Therapy

  2003influential citation
• Gene Therapy Applications to Cancer Treatment

  2003cites this paper
• Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids.

  2003cites this paper
• Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.

  2003cites this paper
• Tumor-targeted gene therapy for nasopharyngeal carcinoma.

  2002cites this paper
• Endocrine-Related Cancer ( 2002 ) 9 115 – 139 Gene therapy of prostate cancer : current and future directions

  2002cites this paper
• Gene therapy of prostate cancer: current and future directions.

  2002cites this paper
• In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter.

  2001cites this paper
• Cancer gene therapy: fringe or cutting edge?

  2001cites this paper